Becton, Dickinson(US:BDX) Prnewswire·2025-09-17 10:50Core Insights - BD (Becton, Dickinson and Company) has successfully placed its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, marking a significant milestone in the adoption of its single-cell multiomics analysis technology [1][2]. Company Overview - BD is recognized as one of the largest global medical technology companies, focusing on improving medical discovery, diagnostics, and care delivery [5]. - The company employs over 70,000 individuals and operates in virtually every country, partnering with organizations to tackle global health challenges [5]. Product Highlights - The BD Rhapsody™ System, introduced in 2017, has been cited in over 700 peer-reviewed publications, demonstrating its impact in the scientific community [2]. - The latest version of the BD Rhapsody™, launched in 2023, features advanced sample processing and cell capture technologies, enhancing the efficiency of next-generation sequencing applications [2]. - Upcoming innovations include the BD OMICS-One™ WTA Next Assay for unlocking genetic information at a lower cost and BD® OMICS-Guard Cryo for sample preservation [6]. Market Demand - The rapid adoption of the BD Rhapsody™ System reflects a critical need for high-performing multiomic assays that maintain data quality while being cost-effective [3]. - The system is positioned to work seamlessly with leading cell sorters and analyzers, indicating a comprehensive end-to-end solution for single-cell analysis [3]. Research and Development - Research conducted by Dr. Andrew Conway Morris at Addenbrooke's Hospital aims to understand immune cell signaling pathways, with the BD Rhapsody™ System facilitating advanced analysis at the single-cell level [2]. - The company continues to innovate its workflows and product offerings to meet the evolving scientific needs [3]. Upcoming Events - The BD Rhapsody™ System will be showcased at the 2025 Annual Meeting of the American Society of Human Genetics and at Advancing Precision Medicine [4].